{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:53:36Z","timestamp":1793224416352,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100017909","name":"Fred C. and Katherine B. Andersen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017909","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mayo Clinic President's Discovery Translation Program Award"},{"name":"Florida Health Grant","award":["#MOG07,SB2500"],"award-info":[{"award-number":["#MOG07,SB2500"]}]},{"name":"Mayo Clinic Florida CAR-T Manufacturing Program Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00262-023-03537-w","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T02:01:16Z","timestamp":1696903276000},"page":"4031-4047","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies"],"prefix":"10.1007","volume":"72","author":[{"given":"Yan","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Qie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha E.","family":"Gadd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alak","family":"Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Rivera-Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant S.","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Dronca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"3537_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang K, Wei G, Liu D (2012) CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 1:36. https:\/\/doi.org\/10.1186\/2162-3619-1-36","journal-title":"Exp Hematol Oncol"},{"key":"3537_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377:2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"3537_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380:45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"key":"3537_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/s0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396:839\u2013852. https:\/\/doi.org\/10.1016\/s0140-6736(20)31366-0","journal-title":"Lancet"},{"key":"3537_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA et al (2022) Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 386:640\u2013654. https:\/\/doi.org\/10.1056\/NEJMoa2116133","journal-title":"N Engl J Med"},{"key":"3537_CR6","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/s0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J et al (2022) Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399:2294\u20132308. https:\/\/doi.org\/10.1016\/s0140-6736(22)00662-6","journal-title":"Lancet"},{"key":"3537_CR7","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A et al (2020) KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 382:1331\u20131342. https:\/\/doi.org\/10.1056\/NEJMoa1914347","journal-title":"N Engl J Med"},{"key":"3537_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s1470-2045(21)00591-x","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR et al (2022) Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 23:91\u2013103. https:\/\/doi.org\/10.1016\/s1470-2045(21)00591-x","journal-title":"Lancet Oncol"},{"key":"3537_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M et al (2022) Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 28:325\u2013332. https:\/\/doi.org\/10.1038\/s41591-021-01622-0","journal-title":"Nat Med"},{"key":"3537_CR10","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.3390\/curroncol29050293","volume":"29","author":"Z Todorovic","year":"2022","unstructured":"Todorovic Z, Todorovic D, Markovic V et al (2022) CAR T cell therapy for chronic lymphocytic leukemia: successes and shortcomings. Curr Oncol 29:3647\u20133657. https:\/\/doi.org\/10.3390\/curroncol29050293","journal-title":"Curr Oncol"},{"key":"3537_CR11","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1126\/science.1061965","volume":"293","author":"JS Thompson","year":"2001","unstructured":"Thompson JS, Bixler SA, Qian F et al (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293:2108\u20132111. https:\/\/doi.org\/10.1126\/science.1061965","journal-title":"Science"},{"key":"3537_CR12","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1158\/1535-7163.MCT-13-1023","volume":"13","author":"R Parameswaran","year":"2014","unstructured":"Parameswaran R, Lim M, Fei F et al (2014) Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R. Mol Cancer Ther 13:1567\u20131577. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-1023","journal-title":"Mol Cancer Ther"},{"key":"3537_CR13","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.4049\/jimmunol.0800933","volume":"183","author":"WN Khan","year":"2009","unstructured":"Khan WN (2009) B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol 183:3561\u20133567. https:\/\/doi.org\/10.4049\/jimmunol.0800933","journal-title":"J Immunol"},{"key":"3537_CR14","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.4049\/jimmunol.1001708","volume":"185","author":"SL Rowland","year":"2010","unstructured":"Rowland SL, Leahy KF, Halverson R, Torres RM, Pelanda R (2010) BAFF receptor signaling aids the differentiation of immature B cells into transitional B cells following tonic BCR signaling. J Immunol 185:4570\u20134581. https:\/\/doi.org\/10.4049\/jimmunol.1001708","journal-title":"J Immunol"},{"key":"3537_CR15","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.humpath.2005.08.005","volume":"36","author":"SJ Rodig","year":"2005","unstructured":"Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM (2005) BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol 36:1113\u20131119. https:\/\/doi.org\/10.1016\/j.humpath.2005.08.005","journal-title":"Hum Pathol"},{"key":"3537_CR16","doi-asserted-by":"publisher","first-page":"eaaw9414","DOI":"10.1126\/scitranslmed.aaw9414","volume":"11","author":"H Qin","year":"2019","unstructured":"Qin H, Dong Z, Wang X et al (2019) CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Sci Transl Med 11:eaaw9414. https:\/\/doi.org\/10.1126\/scitranslmed.aaw9414","journal-title":"Sci Transl Med"},{"key":"3537_CR17","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1111\/j.1537-2995.2006.01033.x","volume":"46","author":"AB Dietz","year":"2006","unstructured":"Dietz AB, Bulur PA, Emery RL, Winters JL, Epps DE, Zubair AC, Vuk-Pavlovi\u0107 S (2006) A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion 46:2083\u20132089. https:\/\/doi.org\/10.1111\/j.1537-2995.2006.01033.x","journal-title":"Transfusion"},{"key":"3537_CR18","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00262-020-02614-8","volume":"69","author":"Z Dong","year":"2020","unstructured":"Dong Z, Cheng WA, Smith DL et al (2020) Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions. Cancer Immunol Immunother 69:2139\u20132145. https:\/\/doi.org\/10.1007\/s00262-020-02614-8","journal-title":"Cancer Immunol Immunother"},{"key":"3537_CR19","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1084\/jem.20100857","volume":"207","author":"JM Hildebrand","year":"2010","unstructured":"Hildebrand JM, Luo Z, Manske MK et al (2010) A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. J Exp Med 207:2569\u20132579. https:\/\/doi.org\/10.1084\/jem.20100857","journal-title":"J Exp Med"},{"key":"3537_CR20","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1182\/blood-2004-02-0762","volume":"104","author":"AJ Novak","year":"2004","unstructured":"Novak AJ, Grote DM, Stenson M et al (2004) Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 104:2247\u20132253. https:\/\/doi.org\/10.1182\/blood-2004-02-0762","journal-title":"Blood"},{"key":"3537_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3960\/jslrt.50.121","volume":"50","author":"H Takahata","year":"2010","unstructured":"Takahata H, Ohara N, Ichimura K et al (2010) BAFF-R is expressed on B-cell lymphomas depending on their origin, and is related to proliferation index of nodal diffuse large B-cell lymphomas. J Clin Exp Hematop 50:121\u2013127. https:\/\/doi.org\/10.3960\/jslrt.50.121","journal-title":"J Clin Exp Hematop"},{"key":"3537_CR22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ et al (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563\u2013571. https:\/\/doi.org\/10.1038\/s41591-018-0010-1","journal-title":"Nat Med"},{"key":"3537_CR23","first-page":"1","volume":"19","author":"CA Jacobson","year":"2021","unstructured":"Jacobson CA (2021) Highlights in CAR T-cell therapy from the 62nd American Society of Hematology Annual Meeting and Exposition. Clin Adv Hematol Oncol 19:1\u201324","journal-title":"Clin Adv Hematol Oncol"},{"key":"3537_CR24","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1038\/s41375-020-0873-2","volume":"34","author":"PM Roessner","year":"2020","unstructured":"Roessner PM, Seiffert M (2020) T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease? Leukemia 34:2012\u20132024. https:\/\/doi.org\/10.1038\/s41375-020-0873-2","journal-title":"Leukemia"},{"key":"3537_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s40425-019-0686-x","volume":"7","author":"R Lemal","year":"2019","unstructured":"Lemal R, Tournilhac O (2019) State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019. J Immunother Cancer 7:202. https:\/\/doi.org\/10.1186\/s40425-019-0686-x","journal-title":"J Immunother Cancer"},{"key":"3537_CR26","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.3389\/fimmu.2018.02285","volume":"9","author":"CR Smulski","year":"2018","unstructured":"Smulski CR, Eibel H (2018) BAFF and BAFF-receptor in B cell selection and survival. Front Immunol 9:2285. https:\/\/doi.org\/10.3389\/fimmu.2018.02285","journal-title":"Front Immunol"},{"key":"3537_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1101\/gad.320192.118","volume":"33","author":"MR Boothby","year":"2019","unstructured":"Boothby MR, Hodges E, Thomas JW (2019) Molecular regulation of peripheral B cells and their progeny in immunity. Genes Dev 33:26\u201348. https:\/\/doi.org\/10.1101\/gad.320192.118","journal-title":"Genes Dev"},{"key":"3537_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/eji.201141957","volume":"42","author":"R Tussiwand","year":"2012","unstructured":"Tussiwand R, Rauch M, Fl\u00fcck LA, Rolink AG (2012) BAFF-R expression correlates with positive selection of immature B cells. Eur J Immunol 42:206\u2013216. https:\/\/doi.org\/10.1002\/eji.201141957","journal-title":"Eur J Immunol"},{"key":"3537_CR29","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3389\/fimmu.2018.00683","volume":"9","author":"W Darwiche","year":"2018","unstructured":"Darwiche W, Gubler B, Marolleau JP, Ghamlouch H (2018) Chronic lymphocytic leukemia B-cell normal cellular counterpart: clues from a functional perspective. Front Immunol 9:683. https:\/\/doi.org\/10.3389\/fimmu.2018.00683","journal-title":"Front Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03537-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03537-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03537-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T03:03:43Z","timestamp":1701918223000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03537-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["3537"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03537-w","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"assertion":[{"value":"27 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HQ has equity with Pepromene Bio, Inc. and Innolifes Inc. The other authors have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was implemented for sample collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}